Nuvation Bio Inc. (NUVB) FY2026 Q2 Balance Sheet

Nuvation Bio Inc. (NUVB) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

744,503,000 US dollars

Current assets

726,432,000 US dollars

Non-current assets

18,071,000 US dollars

Liabilities

490,639,000 US dollars

Current liabilities

86,755,000 US dollars

Non-current liabilities

403,884,000 US dollars

Equity

253,864,000 US dollars

Marketable securities

402,352,000 US dollars

Cash and cash equivalents

258,604,000 US dollars

Accounts receivable, net of allowance for credit loss of $nil and $nil

27,826,000 US dollars

Inventory

19,901,000 US dollars

Prepaid expenses and other current assets

13,861,000 US dollars

Interest receivable on marketable securities

3,888,000 US dollars

Intangible assets, net of accumulated amortization of $2,777 and $1,856, respectively

10,292,000 US dollars

Other non-current assets

3,824,000 US dollars

Operating lease right-of-use assets

3,240,000 US dollars

Property and equipment, net of accumulated depreciation of $1,331 and $1,184, respectively

715,000 US dollars

Accrued expenses

45,204,000 US dollars

Liability related to revenue interest financing agreement, current portion

12,999,000 US dollars

Accounts payable

12,089,000 US dollars

Contract liabilities, current portion

8,855,000 US dollars

Short-term borrowings

5,893,000 US dollars

Current operating lease liabilities

1,715,000 US dollars

Warrant liability

0 US dollars

Convertible debt, net of deferred financing costs of $7,376

242,624,000 US dollars

Non-current liability related to revenue interest financing agreement, net of deferred financing costs of $3,818 and $4,241, respectively

151,122,000 US dollars

Contract liabilities, net of current portion

8,228,000 US dollars

Non-current operating lease liabilities

1,910,000 US dollars

Long-term borrowings, net of deferred financing costs of $3,042

0 US dollars

Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000 shares authorized as of June 30, 2026 and December 31, 2025 respectively 349,822,479 (Class A 348,822,479, Class B 1,000,000) and 346,503,675 (Class A 345,503,675, Class B 1,00,000) shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.

1,429,288,000 US dollars

Accumulated deficit

negative 1,172,813,000 US dollars

Accumulated other comprehensive loss

negative 2,611,000 US dollars

Gross equity (calculated)

1,429,288,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.